Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Market Cap
From what 0 stock analysts predict, the share price for (ASXC) might decrease by NAN% in the next year. This is based on a 12-month average estimation for ASXC. Price targets go from $ to $. The majority of stock analysts believe ASXC is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedASXC 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ASXC. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ASXC.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
Data Not Found! | ||||
In 2023, ASXC generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ASXC's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 22 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - KARL STORZ has acquired a US-based company to establish a surgical robotics hub and enhance its Performance-Guided Surgery™ initiative.
Why It Matters - KARL STORZ's acquisition enhances its position in the growing surgical robotics market, potentially boosting revenue and innovation, which can positively impact stock performance.
Tue, 13 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Asensus Surgical, Inc. (NYSE:ASXC) will discuss its Q2 2024 financial results in a conference call on August 13, 2024, at 4:30 PM ET.
Why It Matters - Asensus Surgical's Q2 earnings call signifies a key moment for investors to assess financial performance and strategic direction, impacting stock valuations and investment decisions.
Tue, 13 Aug 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Asensus Surgical (ASXC) reported a quarterly loss of $0.07 per share, worse than the expected loss of $0.05, but an improvement from a loss of $0.09 per share a year earlier.
Why It Matters - Asensus Surgical's larger-than-expected quarterly loss signals potential operational challenges, impacting investor confidence and stock performance amid comparisons to previous losses.
Thu, 08 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Asensus Surgical, Inc. will release its Q2 2024 financial results on August 13, 2024, after market close, and host a conference call at 4:30 p.m. ET to discuss results and a proposed merger with KARL STORZ.
Why It Matters - Asensus Surgical's upcoming financial results and merger discussions with KARL STORZ could influence stock performance, impacting investor sentiment and market valuation.
Wed, 07 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Asensus Surgical's Special Meeting of Stockholders has been adjourned to August 20, 2024, at 10:00 a.m. ET. The meeting will be conducted virtually.
Why It Matters - The adjournment of Asensus Surgical's stockholder meeting may signal unresolved issues or decisions impacting corporate governance, potentially affecting investor confidence and stock performance.
Mon, 29 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Asensus Surgical, Inc. announced that Glass Lewis recommends stockholders vote "FOR" the merger with KARL STORZ at the Special Meeting on August 7, 2024.
Why It Matters - Glass Lewis's endorsement of Asensus Surgical's merger with KARL STORZ may boost investor confidence, potentially leading to stock price appreciation and increased market interest.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
